ADC Therapeutics
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 274
- Market Cap
- $295.7M
- Introduction
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded b...
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 117
- Registration Number
- NCT04052997
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 18
- Registration Number
- NCT03700294
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸The Sarah Cannon Research Institute (Tennessee Oncology), Nashville, Tennessee, United States
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 136
- Registration Number
- NCT03684694
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 13
- Registration Number
- NCT03685344
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸UCH-MHS Memorial Hospital Centeral, Colorado Springs, Colorado, United States
🇺🇸University of Florida Health Shands Cancer Hospital, Gainesville, Florida, United States
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 78
- Registration Number
- NCT03621982
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut, United States
🇺🇸The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 145
- Registration Number
- NCT03589469
- Locations
- 🇮🇹
U.O. Oncologia ed Ematologia, Rozzano, Milano, Italy
🇮🇹Divisione di Oncoematologia, Milano, Italy
🇬🇧NHS Greater Glasgow and Clyde, Glasgow, Scotland, United Kingdom
Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 21
- Registration Number
- NCT03125200
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Memorial Hospital, New York, New York, United States
🇧🇪Medical Oncology Clinic - Institut Jules Bordet, Brussels, Belgium
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 35
- Registration Number
- NCT02669264
- Locations
- 🇺🇸
University Hospital of Cleveland, Cleveland, Ohio, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The Ohio State University Wexner Medical Center, James Cancer Hospital, Columbus, Ohio, United States
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 183
- Registration Number
- NCT02669017
- Locations
- 🇬🇧
University College London Hospitals, London, United Kingdom
🇮🇹U.O Oncologia e Ematologia - Istituto Clinico Humanitas, Milano, Italy
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 35
- Registration Number
- NCT02588092
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Greenville Health System, Institute for Translational Oncology Research, Greenville, South Carolina, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States